All News

DSB.pill2__0.jpg

WHO Safety Study of Five TNF Inhibitors

Jack Cush, MD

Large scale analysis of adverse events (AEs) in World Health Organization (WHO) VigiAccess database showed no new safety signals associated with long-standing use of five TNFα inhibitors. 

Read Article
RheumNow Podcast square

"Ask Cush Anything" Returns (7.21.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"

Read Article
Covid lung pneumonia corona (keep)

RA Biologics Lower COVID-19 Deaths, but Not Recovery Time

Jack Cush, MD

Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?

Read Article
Giants,women,rheumatology

ICYMI: 25 Great Women in Rheumatology

Jack Cush, MD

I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?

Read Article
Double blind RCT of 101 active AS patients with BASDAI ≥4 showed the IL-23 inhibitor, tildrakizumab was not superior to placebo after 24 weeks (ASAS20: 74% on tildrakizumab 200 mg vs 80% on PBO). Study was terminated after wk 24 interim analysis https://t.co/zZxiAk6A5o https://t.co/P1tNX8BN6C

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/vGt12ul6iy https://t.co/044BScmSYc

Links:

Dr. John Cush RheumNow ( View Tweet)
Belgian study of 312 PsA & 213 SpA pts showed that most had normal spinal Xrays (87.5% PsA, 92% SpA). SpA pts had higher mSASSS than PsA (p<0.05). More Cx (73%) than Lumbar (33%) in PsA; SpA, CX (64%) & LS (71%) evenly distributed https://t.co/Z8JRRuxmWZ https://t.co/8uMiAsk7aA

Links:

Dr. John Cush RheumNow ( View Tweet)
In Memoriam: Dr. K. Frank Austen (1928-2023) Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95. https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R

Links:

Dr. John Cush RheumNow ( View Tweet)
Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/uKArtikNMu

Links:

Dr. John Cush RheumNow ( View Tweet)

RT @Yuz6Yusof : #EULAR2023 Highlights. SpA: OP0059 H2H RCT of SEC vs ADA Biosimilar in bDMARDs naive showed no difference in imaging progression at 2yrs. OP0061 Pooled analyses of UPA RCTs showed low rates of Extra-articular Manifestation. Numerically lower vs PBO for Uveitis

Dr. John Cush RheumNow ( View Tweet)

RT @synovialjoints :The incidence of MACEs at 8 years is low in AS patients treated with NSAIDs. Study of 22929 patients, NSAIDs (SHR: 0.40 [0.32-0.49], p<0.001) and anti-TNFs (SHR: 0.61 [0.47-0.81], p<0.001) associated with a lower risk of MACE, Fakih O, Abst#POS0301, #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @synovialjoints : The International Map of AxSpA (IMAS) of &gt;5k patients: delay mean 7.4+/-9 years, 75% active disease, 60% poor mental health, 21% sick leave, 4.6 GP visits before diagnosis, fear=disease progression, hope=relief of pain, IMAS Abst#POS0298 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

RT @synovialjoints : The definition of early axSpA based on expert consensus after going through the Delphi process by ASAS is that the duration of axial symptoms is equal or less than 2 years. Navarro-Compan V, Abst#OP0055 #EULAR2023

Dr. John Cush RheumNow ( View Tweet)

Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/w1EQEvHbeG https://t.co/aAwKxdNYk1

Links:

Dr. John Cush RheumNow ( View Tweet)
Paradoxical PsO (PP) studied in 2867 RA & 5316 SpA pts. 136 (1.7%) had paradox. Rxn, median 12 mos post TNFi [pustular (60%) or palmoplantar (31%)]. 73% PP favorably switched to other TNFi 46% or non-TNFi 27%. RA PP took SSZ, HCQ, LEF; SpA PP more smokers https://t.co/iYM3EOdSSM https://t.co/sruLP9adx3

Links:

Dr. John Cush RheumNow ( View Tweet)
Why Patients Don't Take Medicines This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost. https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/0dV23VPDQH https://t.co/HfKhji40vU

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd

Links:

Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/DGczkgHtpZ https://t.co/TquFCuh4QG

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 162axSpA pts found that 46.6% reported abnormal sleep behavior, worse in Female patients vs males (P <.001). Such pts were more likely to have depression (P = .015) and worse health-related QoL (HRQOL) (P = .015) https://t.co/a1OoUTPKiV https://t.co/gkjkkdljOh

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×